Cargando…

Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives

BACKGROUND: Availability of tumor material at baseline and disease progression is increasingly important for patient management in non-small-cell lung cancer (NSCLC), especially for the application of targeted therapies like tyrosine kinase inhibitors and for immune checkpoint inhibitor treatment. H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wessels, Sabine, Muley, Thomas, Christopoulos, Petros, Meister, Michael, Heinzmann-Groth, Ingrid, Warth, Arne, Herpel, Esther, Hummler, Simone, Klingmüller, Ursula, Kuon, Jonas, Heussel, Claus-Peter, Eberhardt, Ralf, Herth, Felix J. F., Winter, Hauke, Bischoff, Helge, Stenzinger, Albrecht, Reck, Martin, Huber, Rudolf Maria, Thomas, Michael, Schneider, Marc A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481602/ https://www.ncbi.nlm.nih.gov/pubmed/32953480 http://dx.doi.org/10.21037/tlcr-20-137

Ejemplares similares

Major clinical benefit from adjuvant chemotherapy for stage II–III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis
por: Blasi, Miriam, et al.
Publicado: (2022)

Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples
por: Kriegsmann, Katharina, et al.
Publicado: (2021)

Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC
por: Schneider, Marc A., et al.
Publicado: (2018)

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors
por: Rheinheimer, Stephan, et al.
Publicado: (2020)

FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
por: Richtmann, Sarah, et al.
Publicado: (2019)

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer
por: Dietz, Steffen, et al.
Publicado: (2019)

Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer
por: Magios, Nikolaus, et al.
Publicado: (2021)

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients
por: Schneider, Marc A., et al.
Publicado: (2017)

Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma
por: Fisch, David, et al.
Publicado: (2021)

Pathways regulating the expression of the immunomodulatory protein glycodelin in non-small cell lung cancer
por: Weber, Rebecca, et al.
Publicado: (2018)

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK(+) Lung Cancer Patients with Poor Survival
por: Christopoulos, Petros, et al.
Publicado: (2019)

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report
por: Blasi, Miriam, et al.
Publicado: (2021)

Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report
por: Wiedemann, Christiane, et al.
Publicado: (2022)

Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma
por: Kazdal, Daniel, et al.
Publicado: (2021)

Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report
por: Ball, Markus, et al.
Publicado: (2022)

Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
por: Janke, Florian, et al.
Publicado: (2022)

Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma
por: Schneider, Marc A., et al.
Publicado: (2016)

Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer
por: Kriegsmann, Mark, et al.
Publicado: (2020)

Successful treatment of a recurrent granulation polyp in the airways with high-dose-rate brachytherapy: a case report
por: Polke, M., et al.
Publicado: (2017)

Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis
por: Kreuter, Michael, et al.
Publicado: (2016)

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients
por: Riediger, Anja Lisa, et al.
Publicado: (2016)

Loss of aquaporin-4 expression and putative function in non-small cell lung cancer
por: Warth, Arne, et al.
Publicado: (2011)

Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes
por: Kriegsmann, Mark, et al.
Publicado: (2020)

Expression ratio of the TGFβ-inducible gene MYO10 is prognostic for overall survival of squamous cell lung cancer patients and predicts chemotherapy response
por: Dvornikov, D., et al.
Publicado: (2018)

Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role
por: Warth, A, et al.
Publicado: (2014)

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
por: Daniello, Lea, et al.
Publicado: (2021)

CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation
por: Zhao, Jing, et al.
Publicado: (2017)

Differential diagnostic value of CD5 and CD117 expression in thoracic tumors: A large scale study of 1465 non-small cell lung cancer cases
por: Kriegsmann, Mark, et al.
Publicado: (2015)

Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis
por: Angeles, Arlou Kristina, et al.
Publicado: (2021)

Cancer cell specific inhibition of Wnt/β-catenin signaling by forced intracellular acidification
por: Melnik, Svitlana, et al.
Publicado: (2018)

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA
por: Dietz, Steffen, et al.
Publicado: (2020)

Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study
por: Schneider, Marc A., et al.
Publicado: (2022)

Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies
por: Christopoulos, Petros, et al.
Publicado: (2021)

Iron accumulation in tumor-associated macrophages marks an improved overall survival in patients with lung adenocarcinoma
por: Thielmann, Carl Maximilian, et al.
Publicado: (2019)

Multimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach
por: Klotz, Laura V., et al.
Publicado: (2022)

Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition
por: Baum, Philip, et al.
Publicado: (2021)

Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer
por: Mountzios, G., et al.
Publicado: (2021)

The minimal important difference for target lobe volume reduction after endoscopic valve therapy
por: Gompelmann, D, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p4jd509ii7nha6jnntju98043a